New strategies for managing drug spend: RA, Cancer, Hep C
New strategies for managing drug spend: RA, Cancer, Hep CThe proliferation of specialty drugs has prompted new techniques for keeping costs in tow.
Payers to pharma: Here’s what we’re missing in hep C drugsA Precision for Value survey highlights what can be done in order to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.
Bristol-Myers Squibb withdraws potential hep C combo therapyBristol-Myers Squibb (BMS) will not pursue FDA approval of its hepatitis C (HCV) treatment, a dual regimen of daclatasvir and asunaprevir, and has withdrawn its new drug application (NDA) for asunaprevir, an NS3/4A protease inhibitor.
Report: Specialty drug costs will skyrocket in next two yearsCostly treatments are expected to drive unprecedented growth in U.S. drug spending over the next two years. Some analysts say that’s not good news for consumers or most pharmacists.
BLOG: Hepatitis C and an expanding specialty pharmacy market basket of drugs